Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I , Open Label, Multi-center Study to Assess the Safety and Tolerability of KGX101 Mono and Combo Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients

NCT07260305 is registered in ClinicalTrials.gov with Kangabio AUSTRALIA LTD PTY as lead sponsor.

NCT NCT07260305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07260305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I , Open Label, Multi-center Study to Assess the Safety and Tolerability of KGX101 Mono and Combo Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Lead sponsor
Kangabio AUSTRALIA LTD PTY
Phase
Phase 1
Overall status
Recruiting
Start date
November 27, 2024
Completion date
March 30, 2027
Enrollment
57 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors